Beyond Air Inc (XAIR)

May 20, 2025, 8:00 AM EDT - 17 days ago

Beyond Air Schedules Fiscal Year End 2025 Financial Results Conference Call and Webcast

Apr 21, 2025, 4:05 PM EDT - 6 weeks ago

NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism

Apr 15, 2025, 4:05 PM EDT - 7 weeks ago

NeuroNOS Appoints Nobel Prize Laureate, Professor Dan Shechtman, to Scientific Advisory Board

Apr 9, 2025, 4:05 PM EDT - 2 months ago

Beyond Air Publishes Article in Annals of the American Thoracic Society Journal Highlighting NTM-PD Patients' Ability to Safely Self-Administer High-Dose Intermittent iNO Treatments Using the LungFit™ GO at Home

Mar 31, 2025, 8:00 AM EDT - 2 months ago

Beyond Air Announces Vanderbilt University Medical Center as First Luminary Site

Mar 24, 2025, 4:05 PM EDT - 2 months ago

NeuroNOS Secures $2.0 Million in Funding to Advance Development of an Innovative Autism Therapy

Mar 11, 2025, 7:30 AM EDT - 3 months ago

Beyond Air Announces Agreements Expanding Global Distribution of LungFit® PH

Mar 6, 2025, 4:05 PM EST - 3 months ago

Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences

Feb 10, 2025, 7:25 PM EST - 4 months ago

Beyond Air, Inc. (XAIR) Q3 2025 Earnings Call Transcript

Feb 10, 2025, 4:05 PM EST - 4 months ago

Beyond Air® Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update

Feb 5, 2025, 9:29 AM EST - 4 months ago

Beyond Air® Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

Jan 27, 2025, 4:05 PM EST - 4 months ago

Beyond Air® Schedules Third Fiscal Quarter 2025 Financial Results Conference Call and Webcast

Jan 24, 2025, 9:15 AM EST - 4 months ago

Beyond Air® Announces LungFit® PH Receives Market Authorization in Australia

Dec 9, 2024, 11:00 AM EST - 6 months ago

National Advertising Division Recommends Beyond Air Discontinue or Modify Comparative Safety Claims for its iNO Products

Dec 3, 2024, 4:05 PM EST - 6 months ago

Beyond Cancer Announces Approval by the Israeli Ministry of Health to Conduct a Phase 1b Clinical Trial Utilizing Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) in Combination with Anti-PD-1 Therapy

Dec 2, 2024, 7:30 AM EST - 6 months ago

Beyond Air Receives CE Mark in Europe for the LungFit® PH System

Nov 26, 2024, 7:30 AM EST - 6 months ago

NeuroNOS Appoints Nobel Laureate, Roger D. Kornberg, to Scientific Advisory Board

Nov 14, 2024, 4:05 PM EST - 7 months ago

Beyond Air to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 11, 2024, 7:56 PM EST - 7 months ago

Beyond Air, Inc. (XAIR) Q2 2025 Earnings Call Transcript

Nov 11, 2024, 4:05 PM EST - 7 months ago

Beyond Air® Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update

Oct 29, 2024, 4:22 PM EDT - 7 months ago

Beyond Air® Schedules Second Fiscal Quarter 2025 Financial Results Conference Call and Webcast

Oct 7, 2024, 7:00 AM EDT - 8 months ago

Beyond Cancer to Present Preclinical Data of Ultra-High Concentration Nitric Oxide (UNO) Low Volume Therapy at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 2, 2024, 7:30 AM EDT - 8 months ago

Beyond Air Partners with Healthcare Links to Expand Access to LungFit® PH System Through Group Purchasing Organizations and Integrated Delivery Networks

Sep 27, 2024, 7:34 AM EDT - 9 months ago

Beyond Air Provides LungFit® PH System to U.S. Naval Hospital Guam for Neonatal Critical Care in Partnership with TrillaMed

Sep 27, 2024, 7:32 AM EDT - 9 months ago

Beyond Air Announces Termination of the Loan and Security Agreements with Avenue Capital

Sep 27, 2024, 7:30 AM EDT - 9 months ago

Beyond Air Announces $20.6 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules

Sep 23, 2024, 8:00 AM EDT - 9 months ago

Beyond Air to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Jul 31, 2024, 4:15 PM EDT - 11 months ago

Beyond Air® Publishes Peer-Reviewed Journal Article in Scientific Reports with Clinical Data Showing Nitric Oxide was Safe and Beneficial Adjunct Therapy for Subjects with Viral Pneumonia

Jul 23, 2024, 4:05 PM EDT - 11 months ago

Beyond Air® to Report First Fiscal Quarter 2025 Financial Results on August 6

Jul 16, 2024, 4:05 PM EDT - 11 months ago

Beyond Air® To Participate in the BTIG Virtual Biotechnology Conference 2024

Jun 24, 2024, 5:48 PM EDT - 1 year ago

Beyond Air, Inc. (XAIR) Q4 2024 Earnings Call Transcript

Jun 24, 2024, 4:15 PM EDT - 1 year ago

Beyond Air® Reports Fiscal Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Jun 24, 2024, 3:32 AM EDT - 1 year ago

Enerpac Tool Group, Singular Genomics Systems And 3 Stocks To Watch On Monday

EPAC OMIC ITI STOK

Jun 13, 2024, 4:05 PM EDT - 1 year ago

Beyond Air® Appoints David Webster as Chief Commercial Officer

Jun 3, 2024, 7:00 AM EDT - 1 year ago

Beyond Cancer Presents First-in-Class Clinical Data Showing an Immunogenic Response in Subjects with r/r Unresectable Solid Tumors Treated with Ultra-High Concentration Nitric Oxide (UNO)

May 23, 2024, 4:09 PM EDT - 1 year ago

Beyond Air® Schedules Fiscal Year End 2024 Financial Results Conference Call and Webcast

Mar 20, 2024, 9:00 AM EDT - 1 year ago

Beyond Air® Announces Pricing of $16.0 Million Registered Direct Offering of Common Stock and Warrants

Feb 13, 2024, 2:37 AM EST - 1 year ago

Beyond Air, Inc. (XAIR) Q3 2024 Earnings Call Transcript

Feb 12, 2024, 4:05 PM EST - 1 year ago

Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2024

Jan 18, 2024, 8:00 AM EST - 1 year ago

Beyond Air® Schedules Third Fiscal Quarter 2024 Financial Results Conference Call and Webcast

Dec 27, 2023, 7:30 AM EST - 1 year ago

Beyond Cancer™ Phase 1 Study Clears Cohort 1 in Patients with Advanced Relapsed or Refractory Unresectable Primary or Metastatic Cutaneous or Subcutaneous Solid Tumors

Nov 15, 2023, 4:05 PM EST - 1 year ago

Beyond Air® To Participate in the 35th Annual Piper Sandler Healthcare Conference

Nov 13, 2023, 7:07 PM EST - 1 year ago

Beyond Air, Inc. (XAIR) Q2 2024 Earnings Call Transcript

Nov 13, 2023, 4:05 PM EST - 1 year ago

Beyond Air® Reports Financial Results for Second Quarter of Fiscal Year 2024

Nov 3, 2023, 12:00 PM EDT - 1 year ago

Beyond Cancer™ Presents Positive First-in-Human Clinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Oct 19, 2023, 4:05 PM EDT - 1 year ago

Beyond Air® Schedules Second Fiscal Quarter 2024 Financial Results Conference Call and Webcast

Oct 17, 2023, 4:05 PM EDT - 1 year ago

Beyond Air® To Participate in the Truist Securities BioPharma Symposium

Oct 17, 2023, 7:30 AM EDT - 1 year ago

Beyond Cancer™ Publishes Pre-Clinical Data in Cells Demonstrating that the Combination of Ultra-High Concentration Nitric Oxide (UNO) and Anti-mPD-1 Therapy Improves Tumor Regression Rates and Survival in Mice

Oct 16, 2023, 7:30 AM EDT - 1 year ago

Beyond Cancer™ Presents Positive Preclinical Data for Ultra-High Concentration Nitric Oxide (UNO) in Combination with Checkpoint Inhibitor Therapy During the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 16, 2023, 7:00 AM EDT - 1 year ago

Beyond Air® Receives Innovative Technology Contract from Vizient for LungFit®PH